Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Abstract

We are so grateful to receive the informative comments from Professor Naoshi Nishida on our publication. We would like to describe two additional issues to think about further. Because Professor.Nishida explained in detail the scientific background of using tyrosine kinase inhibitor (TKI) use after ATE/BEV failure and the ongoing phase II trial regarding TKI treatment, we tried to focus on other options such as immune check point inhibitor (ICI)-based treatment and radiation after ATE/BEV